Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422457 | 0.85 | LMNA (0.41) | SRD5A2ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL11877213 | 0.81 | TSHR (0.52) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL10900089 | 0.81 | TSHR (0.52) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL5576679 | 0.78 | TSHR (0.48) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL5576092 | 0.78 | TSHR (0.48) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL2852452 | 0.78 | ANPEP (0.52) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL9636818 | 0.78 | TSHR (0.48) | TSHRTP53CA1CA2SRD5A2 | |
| SCHEMBL5640199 | 0.77 | CA1 (0.50) | TSHRCA1CA2ALDH1A1CA12 | |
| SCHEMBL28550398 | 0.77 | CES1 (0.47) | CES2CES1 | |
| SCHEMBL1596408 | 0.77 | TSHR (0.67) | TSHRTP53CA1CA2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006110961-A2 | NOVEL CORROSION INHIBITING MATERIALS | A J SCIENTIFIC PTY LTD (AU) | 2006-10-26 | — | — | WO | claimed |
| EP-1368016-B1 | PARENTERAL DOSAGE FORMS COMPRISING A SUSPENSION OF TRAMADOL SALT AND DICLOFENAC SALT | GRUENENTHAL GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-0126364-B1 | METABOLICALLY ACTIVE PREPARATIONS OBTAINED FROM YEAST OF ANY TYPE | HASUNOR A.G. (CH) | 1987-09-09 | — | — | EP | claimed |
| US-20160287707-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| CN-102239255-B | Improve Perhydrolase to generate for enzymatic peracid | E. I. DU PONT DE NEMOURS AND CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| CN-104411822-A | Enzymes useful for peracid production | DU PONT | 2015-03-11 | — | — | CN | disclosed |
| CN-104364384-A | Enzymes useful for peracid production | DU PONT | 2015-02-18 | — | — | CN | disclosed |
| CN-104350153-A | Enzymes useful for peracid production | DU PONT | 2015-02-11 | — | — | CN | disclosed |
| US-20140303145-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140018346-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2014-01-16 | — | — | US | disclosed |
| US-20080287417-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | EBNER ANDREAS | 2008-11-20 | — | — | US | disclosed |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005097760-A1 | HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20040077232-A1 | Pharmaceutical compositions | EBNER ANDREAS (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1043304-B1 | Method for producing (hydroxyalkyl)alicyclic carboxylic acids and intermediates therefor | NIPPON CATALYTIC CHEM IND (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1372611-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | Novartis AG (CH) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076432-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-6444843-B1 | CATALYTIC OXIDATION | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| EP-1043304-A1 | Method for producing (hydroxyalkyl)alicyclic carboxylic acids and intermediates therefor | Nippon Shokubai Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5584917-A | POLYSILOXANE WITH TERT-AMINO GROUP; DURABILITY, ONE STEP TREATMENT | TAIHO INDUSTRIES CO., LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018346-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | SI, SPAST, ADCYAP1R1 | TSHR 3298/4885TP53 787/4885CA1 2370/4885 |
| US-20140303145-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | SI, SPAST, ADCYAP1R1 | TSHR 3298/4885TP53 787/4885CA1 2370/4885 |
| US-20080287417-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | SI, SPAST, ADCYAP1R1 | TSHR 3202/4885TP53 737/4885CA1 2424/4885 |
| US-20160287707-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER | SI, SPAST, ADCYAP1R1 | TSHR 3298/4885TP53 787/4885CA1 2370/4885 |
| US-20050239751-A1 | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses | HAVCR2, HCCS, AADAC | TSHR 4658/4885TP53 317/4885CA1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.